Near-Monopolies On HCV Diagnostics Curb Competition, Keep Prices High, Research Finds

Monopoly prices of diagnostic tools and lack of competition in the market constitute a barrier to treatment for people with hepatitis C virus (HCV), but the increased use of “open” diagnostic platforms could reduce prices, a health advocacy research study has found.







